What is a stock summary page? Click here for an overview.
Business Description
Daito Pharmaceutical Co Ltd
ISIN : JP3486150000
Description
Daito Pharmaceutical Co Ltd is engaged in the research and development of pharmaceutical products. The company also undertakes contract manufacturing.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.29 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 1.9 | |||||
| Interest Coverage | 37.07 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.51 | |||||
| Beneish M-Score | -2.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.7 | |||||
| 3-Year EBITDA Growth Rate | -5.7 | |||||
| 3-Year EPS without NRI Growth Rate | -12.6 | |||||
| 3-Year FCF Growth Rate | 3.6 | |||||
| 3-Year Book Growth Rate | 7.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 4.84 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.47 | |||||
| 9-Day RSI | 58.14 | |||||
| 14-Day RSI | 59.49 | |||||
| 3-1 Month Momentum % | -3.11 | |||||
| 6-1 Month Momentum % | -10.87 | |||||
| 12-1 Month Momentum % | -12.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | |||||
| Quick Ratio | 1.29 | |||||
| Cash Ratio | 0.19 | |||||
| Days Inventory | 199.58 | |||||
| Days Sales Outstanding | 91.14 | |||||
| Days Payable | 55.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.97 | |||||
| Dividend Payout Ratio | 0.47 | |||||
| 3-Year Dividend Growth Rate | 12.8 | |||||
| Forward Dividend Yield % | 3.2 | |||||
| 5-Year Yield-on-Cost % | 5.13 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | -9.98 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 19.06 | |||||
| Operating Margin % | 6.5 | |||||
| Net Margin % | 5.6 | |||||
| FCF Margin % | -2.31 | |||||
| ROE % | 5.1 | |||||
| ROA % | 3.38 | |||||
| ROIC % | 2.91 | |||||
| 3-Year ROIIC % | -7.09 | |||||
| ROC (Joel Greenblatt) % | 7.05 | |||||
| ROCE % | 6.4 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.99 | |||||
| Forward PE Ratio | 12.13 | |||||
| PE Ratio without NRI | 16.23 | |||||
| Shiller PE Ratio | 8.85 | |||||
| PS Ratio | 0.72 | |||||
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 0.66 | |||||
| Price-to-Operating-Cash-Flow | 6.73 | |||||
| EV-to-EBIT | 10.65 | |||||
| EV-to-EBITDA | 6.9 | |||||
| EV-to-Revenue | 0.87 | |||||
| EV-to-FCF | -37.64 | |||||
| Price-to-GF-Value | 0.88 | |||||
| Price-to-Projected-FCF | 0.78 | |||||
| Price-to-Median-PS-Value | 0.8 | |||||
| Price-to-Graham-Number | 0.69 | |||||
| Price-to-Net-Current-Asset-Value | 2.13 | |||||
| Earnings Yield (Greenblatt) % | 9.39 | |||||
| FCF Yield % | -3.31 | |||||
| Forward Rate of Return (Yacktman) % | -7.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Daito Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 47,369 | ||
| EPS (TTM) (円) | 171.17 | ||
| Beta | 0.33 | ||
| 3-Year Sharpe Ratio | -0.39 | ||
| 3-Year Sortino Ratio | -0.49 | ||
| Volatility % | 19.49 | ||
| 14-Day RSI | 59.49 | ||
| 14-Day ATR (円) | 39.467058 | ||
| 20-Day SMA (円) | 2169.1 | ||
| 12-1 Month Momentum % | -12.98 | ||
| 52-Week Range (円) | 1992 - 2573 | ||
| Shares Outstanding (Mil) | 15.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Daito Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Daito Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Daito Pharmaceutical Co Ltd Frequently Asked Questions
What is Daito Pharmaceutical Co Ltd(TSE:4577)'s stock price today?
The current price of TSE:4577 is 円2224.00. The 52 week high of TSE:4577 is 円2573.00 and 52 week low is 円1992.00.
When is next earnings date of Daito Pharmaceutical Co Ltd(TSE:4577)?
The next earnings date of Daito Pharmaceutical Co Ltd(TSE:4577) is .
Does Daito Pharmaceutical Co Ltd(TSE:4577) pay dividends? If so, how much?
The Dividend Yield % of Daito Pharmaceutical Co Ltd(TSE:4577) is 2.97% (As of Today), Highest Dividend Payout Ratio of Daito Pharmaceutical Co Ltd(TSE:4577) was 0.47. The lowest was 0.13. And the median was 0.14. The Forward Dividend Yield % of Daito Pharmaceutical Co Ltd(TSE:4577) is 3.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers